These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10552233)

  • 1. The rise and fall of tolcapone.
    Colosimo C
    J Neurol; 1999 Oct; 246(10):880-2. PubMed ID: 10552233
    [No Abstract]   [Full Text] [Related]  

  • 2. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 6. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.
    Olanow CW
    Arch Neurol; 2000 Feb; 57(2):263-7. PubMed ID: 10681087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder".
    Moroz G; Magni G; Fava M
    J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
    Agid Y; Destée A; Durif F; Montastruc JL; Pollak P
    Lancet; 1997 Sep; 350(9079):712-3. PubMed ID: 9291909
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST; Ernst ME
    Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highlights of the North American and European experiences.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mosé Da Prada and the discovery of tolcapone.
    Borroni E; Borgulya J; Zürcher G
    J Neural Transm Suppl; 1998; 52():XIII-XVI. PubMed ID: 9564601
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone].
    Avila A; Kulisevsky J
    Neurologia; 1998; 13 Suppl 1():66-71. PubMed ID: 9859687
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolcapone and fulminant hepatitis.
    Assal F; Spahr L; Hadengue A; Rubbia-Brandt L; Burkhard PR
    Lancet; 1998 Sep; 352(9132):958. PubMed ID: 9752821
    [No Abstract]   [Full Text] [Related]  

  • 20. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.